Chronic treatment with rivastigmine in patients with Alzheimer's disease: a study on primary motor cortex excitability tested by 5 Hz-repetitive transcranial magnetic stimulation
| Autor: | Mauro Ceccanti, Maurizio Inghilleri, Francesca Gilio, C. Cambieri, C. De Lena, Fabrizia D'Antonio, Alessandro Trebbastoni |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
medicine.medical_treatment Phenylcarbamates Rivastigmine Electromyography Functional Laterality Alzheimer Disease Physiology (medical) Alzheimer’s disease (AD) Synaptic plasticity Repetitive transcranial magnetic stimulation (rTMS) Cholinesterase inhibitor medicine Reaction Time Humans Longitudinal Studies Evoked potential Muscle Skeletal Aged Aged 80 and over Analysis of Variance medicine.diagnostic_test Motor Cortex Neuropsychological test Evoked Potentials Motor Transcranial Magnetic Stimulation Sensory Systems Transcranial magnetic stimulation Neuroprotective Agents Neurology Anesthesia Case-Control Studies Synaptic plasticity Silent period Female Neurology (clinical) Primary motor cortex Psychology Mental Status Schedule medicine.drug |
| Zdroj: | Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 123(5) |
| ISSN: | 1872-8952 |
| Popis: | Objective To investigate changes in cortical excitability and short-term synaptic plasticity we delivered 5 Hz repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex in 11 patients with mild-to-moderate Alzheimer’s disease (AD) before and after chronic therapy with rivastigmine. Methods Resting motor threshold (RMT), motor evoked potential (MEP), cortical silent period (CSP) after single stimulus and MEP facilitation during rTMS trains were tested three times during treatment. All patients underwent neuropsychological tests before and after receiving rivastigmine. rTMS data in patients were compared with those from age-matched healthy controls. Results At baseline, RMT was significantly lower in patients than in controls whereas CSP duration and single MEP amplitude were similar in both groups. In patients, rTMS failed to induce the normal MEP facilitation during the trains. Chronic rivastigmine intake significantly increased MEP amplitude after a single stimulus, whereas it left the other neurophysiological variables studied unchanged. No significant correlation was found between patients’ neuropsychological test scores and TMS measures. Conclusions Chronic treatment with rivastigmine has no influence on altered cortical excitability and short-term synaptic plasticity as tested by 5 Hz-rTMS. Significance The limited clinical benefits related to cholinesterase inhibitor therapy in patients with AD depend on factors other than improved plasticity within the cortical glutamatergic circuits. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect